Skip to content

Intracochlear Triamcinolone acetonide in sudden sensorineural hearing loss patients - a prospective observer blinded randomized study

Status
Not yet recruiting
Phases
Phase 2
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2024-513145-36-00
Enrollment
40
Registered
2024-12-11
Start date
Unknown
Completion date
Unknown
Last updated
2024-12-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sudden sensori neural hearing loss

Brief summary

Mean hearing threshold shift on day 30 postoperatively in three sequential frequencies most affected by SSHL.

Detailed description

Freiburger monosyllable speech intelligibility test and the oldenburg sentence test on day 30 postoperatively, Intensity of tinnitus, quality of speech intelligibility and the perception of the own health condition on day 30 postoperatively, Proteomics of the perilymph, Concentration of triamcinolone acetonide (if applicable) and proteins depending on the results of the perilymph proteomics

Interventions

DRUGVolon® A 40 mg-Kristallsuspension-Spritzampulle

Sponsors

Medical University Of Vienna
Lead SponsorOTHER

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Design outcomes

Primary

MeasureTime frame
Mean hearing threshold shift on day 30 postoperatively in three sequential frequencies most affected by SSHL.

Secondary

MeasureTime frame
Freiburger monosyllable speech intelligibility test and the oldenburg sentence test on day 30 postoperatively, Intensity of tinnitus, quality of speech intelligibility and the perception of the own health condition on day 30 postoperatively, Proteomics of the perilymph, Concentration of triamcinolone acetonide (if applicable) and proteins depending on the results of the perilymph proteomics

Countries

Austria

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026